Help ?

IGMIN: あなたがここにいてくれて嬉しいです. お願いクリック '新しいクエリを作成してください' 当ウェブサイトへの初めてのご訪問で、さらに情報が必要な場合は.

すでに私たちのネットワークのメンバーで、すでに提出した質問に関する進展を追跡する必要がある場合は, クリック '私のクエリに連れて行ってください.'

Subjects/Topics

Welcome to IgMin Research – an Open Access journal uniting Biology Group, Medicine Group, and Engineering Group. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.

Members

We foster partnerships that bring together diverse perspectives to drive faster solutions.

Articles

We foster partnerships that bring together diverse perspectives to drive faster solutions.

Explore Content

We foster partnerships that bring together diverse perspectives to drive faster solutions.

Identify Us

We foster partnerships that bring together diverse perspectives to drive faster solutions.

IgMin Corporation

Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.

Publications Support
publications.support@igmin.org
E-Books Support
ebooks.support@igmin.org
Webinars & Conferences Support
webinarsandconference@igmin.org
Content Writing Support
contentwriting.support@igmin.org

Search

Explore Section

Content for the explore section slider goes here.

Abstract

要約 at IgMin Research

We foster partnerships that bring together diverse perspectives to drive faster solutions.

Medicine Group Review Article 記事ID: igmin185

Diagnostic Challenges in Pancreatic Tumors

Gastroenterology DOI10.61927/igmin185 Affiliation

Affiliation

    1Carol Davila University of Medicine, Bucharest, Romania

    2Department of General Surgery, Bagdasar-Arseni Clinical Emergency Hospital, Bucharest, Romania

1.9k
VIEWS
143
DOWNLOADS
Connect with Us

要約

Background: Pancreatic tumors have a large diversity, with an increasing incidence and mortality. Although the diagnosis methods have improved in recent years, establishing a diagnosis and a histopathological type of pancreatic tumor can still pose a challenge. 
Aim: We propose to present a concise list of difficulties regarding the clinical, biological, and imagistic diagnosis of pancreatic tumors. 
Key information: The clinical manifestations of pancreatic tumors depend on their location and size, on the presence of metastatic lesions, but the difficulty of orientation towards this diagnosis is determined by the fact that most lesions are asymptomatic or present in the early stages of non-specific symptoms. The usual biological parameters are non-specific in pancreatic tumors in the early stages, but studies are underway regarding a series of biomarkers, genetic micro-sequences, or inorganic nanomaterials that could be used in the early diagnosis of pancreatic cancers. An essential stage in the diagnosis of pancreatic tumors is represented by imaging investigations, which are associated with endoscopic and tumor biopsy procedures and can outline a picture regarding the presence of the tumor at the level of the pancreas, the relationship with the neighboring organs, the nature of the tumor and the histopathological type. There are a series of indications and limitations regarding each of these investigations, trying to develop various algorithms for the diagnosis of pancreatic tumors. 
Conclusion: The medical research conducted to develop new diagnostic procedures has the objective of ensuring an early diagnosis of pancreatic tumors, in a stage that offers the best chances of recovery for the patient.

数字

参考文献

    1. Wu W, He X, Yang L, Wang Q, Bian X, Ye J, Li Y, Li L. Rising trends in pancreatic cancer incidence and mortality in 2000-2014. Clin Epidemiol. 2018 Jul 9;10:789-797. doi: 10.2147/CLEP.S160018. PMID: 30022856; PMCID: PMC6042490.
    2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5. PMID: 28055103.
    3. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016 Nov 28;22(44):9694-9705. doi: 10.3748/wjg.v22.i44.9694. PMID: 27956793; PMCID: PMC5124974.
    4. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019 Feb;10(1):10-27. doi: 10.14740/wjon1166. Epub 2019 Feb 26. PMID: 30834048; PMCID: PMC6396775.
    5. Klein A. Pancreatic cancer: a growing burden. The Lancet - Gastroenterology and Hepatoloy 2019; 4(12):895-6.
    6. Dumitrascu T. Tumorile pancreatice. In: Beuran M, Patrascu T, editors. Curs de chirurgie pentru studentii din anul IV si V. 2 ed. Bucuresti: Editura Universitara Carol Davila. 2020; 315-40.
    7. Buchler M. Neoplasms of the pancreas. In: Buchler M, Uhl W, Malfertheiner P, Sarr M, editors. Diseases of the pancreas. Karger. 2004; 125-67.
    8. Copur MS, Talmon GA, Wedel W, Hart JD, Merani S, Vargasi LM. Hereditary vs Familial Pancreatic Cancer: Associated Genetic Syndromes and Clinical Perspective. Oncology (Williston Park). 2020 Jun 10;34(6):196-201. PMID: 32609864.
    9. Ma DM, Dong XW, Han X, Ling Z, Lu GT, Sun YY, Yin XD. Pancreatitis and Pancreatic Cancer Risk. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231164875. doi: 10.1177/15330338231164875. PMID: 36972517; PMCID: PMC10052482.
    10. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001 Jul 11;286(2):169-70. doi: 10.1001/jama.286.2.169. PMID: 11448279.
    11. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grützmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003 Feb 5;95(3):214-21. doi: 10.1093/jnci/95.3.214. PMID: 12569143.
    12. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009 Apr;10(4):400-8. doi: 10.1016/S1470-2045(09)70041-5. PMID: 19341971.
    13. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995 Oct 12;333(15):970-4. doi: 10.1056/NEJM199510123331504. PMID: 7666916.
    14. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996 Dec 1;56(23):5360-4. PMID: 8968085.
    15. Ozçelik H, Schmocker B, Di Nicola N, Shi XH, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S, Redston M. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet. 1997 May;16(1):17-8. doi: 10.1038/ng0597-17. PMID: 9140390.
    16. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002 Jul 1;62(13):3789-93. PMID: 12097290.
    17. Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018 May 21;24(19):2047-2060. doi: 10.3748/wjg.v24.i19.2047. PMID: 29785074; PMCID: PMC5960811.
    18. Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin Oncol. 2007 Aug;34(4):284-94. doi: 10.1053/j.seminoncol.2007.05.005. PMID: 17674956; PMCID: PMC2680914.
    19. Noy A, Bilezikian JP. Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab. 1994 Nov;79(5):1223-31. doi: 10.1210/jcem.79.5.7962312. PMID: 7962312.
    20. Gullo L, Pezzilli R, Morselli-Labate AM; Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994 Jul 14;331(2):81-4. doi: 10.1056/NEJM199407143310203. PMID: 8208269.
    21. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg. 1993 Feb;159(2):101-7. PMID: 8098623.
    22. Jain M, Howe GR, St Louis P, Miller AB. Coffee and alcohol as determinants of risk of pancreas cancer: a case-control study from Toronto. Int J Cancer. 1991 Feb 1;47(3):384-9. doi: 10.1002/ijc.2910470313. PMID: 1993545.
    23. Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, Yamaguchi T, Izawa K, Tsunoda T, Yoshino R, et al. Collective review of small carcinomas of the pancreas. Ann Surg. 1986 Jan;203(1):77-81. doi: 10.1097/00000658-198601000-00013. PMID: 3942423; PMCID: PMC1251042.
    24. Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. Cancer. 1991 Jan 15;67(2):486-93. doi: 10.1002/1097-0142(19910115)67:2<486::aid-cncr2820670228>3.0.co;2-1. PMID: 1985741.
    25. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001 Sep;121(3):640-5. doi: 10.1053/gast.2001.27210. PMID: 11522748.
    26. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006 Feb 1;73(3):485-92. PMID: 16477897.
    27. DiMagno E. Cancer of the pancreas and biliary tract. In: Winawer S, editor. Management of gastrointestinal diseases.New York: Gower Medical Publishing; 1992; 1-37.
    28. Tomasello G, Ghidini M, Costanzo A, Ghidini A, Russo A, Barni S, Passalacqua R, Petrelli F. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. J Gastrointest Oncol. 2019 Apr;10(2):259-269. doi: 10.21037/jgo.2018.12.08. PMID: 31032093; PMCID: PMC6465486.
    29. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8. PMID: 14974761.
    30. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012 Jun;3(2):105-19. doi: 10.3978/j.issn.2078-6891.2011.021. PMID: 22811878; PMCID: PMC3397644.
    31. Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014 Aug;35(8):7459-65. doi: 10.1007/s13277-014-1995-9. Epub 2014 May 1. PMID: 24789274.
    32. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009 Sep;198(3):333-9. doi: 10.1016/j.amjsurg.2008.12.031. Epub 2009 Apr 17. PMID: 19375064.
    33. Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol. 2020 May 27;10:831. doi: 10.3389/fonc.2020.00831. PMID: 32537434; PMCID: PMC7267066.
    34. Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, Appetecchia M. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel). 2019 Aug 4;11(8):1113. doi: 10.3390/cancers11081113. PMID: 31382663; PMCID: PMC6721814.
    35. Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin AG, Chayvialle JA, Scoazec JY, Lombard-Bohas C. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer. 2012 Aug;48(12):1766-73. doi: 10.1016/j.ejca.2011.11.005. Epub 2011 Nov 29. PMID: 22133573.
    36. Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab. 1995 Aug;80(8):2273-8. doi: 10.1210/jcem.80.8.7629220. PMID: 7629220.
    37. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005 Mar;31(2):164-9. doi: 10.1016/j.ejso.2004.09.007. PMID: 15698733.
    38. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A, Zaikin A, Smith RC, Jacobs IJ, Menon U, Costello E, Pereira SP, Timms JF. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015 Feb 1;21(3):622-31. doi: 10.1158/1078-0432.CCR-14-0365. Epub 2014 Jun 17. PMID: 24938522; PMCID: PMC4181906.
    39. Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW, Zöller M. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015 Jun 1;136(11):2616-27. doi: 10.1002/ijc.29324. Epub 2014 Nov 25. PMID: 25388097.
    40. Yang F, Jin C, Subedi S, Lee CL, Wang Q, Jiang Y, Li J, Di Y, Fu D. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev. 2012 Oct;38(6):566-79. doi: 10.1016/j.ctrv.2012.02.003. PMID: 22655679.
    41. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004 Apr 1;10(7):2386-92. doi: 10.1158/1078-0432.ccr-03-0165. PMID: 15073115.
    42. Al-Hawary M, Francis I, Chari S, Fishman E, Hough D, Lu D. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 2014; 270:248-60.
    43. Ahn SS, Kim MJ, Choi JY, Hong HS, Chung YE, Lim JS. Indicative findings of pancreatic cancer in prediagnostic CT. Eur Radiol. 2009 Oct;19(10):2448-55. doi: 10.1007/s00330-009-1422-6. Epub 2009 May 5. PMID: 19415290.
    44. Raman SP, Horton KM, Fishman EK. Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J. 2012 Nov-Dec;18(6):511-22. doi: 10.1097/PPO.0b013e318274a461. PMID: 23187837.
    45. Yang R, Lu M, Qian X, Chen J, Li L, Wang J, Zhang Y. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. J Cancer Res Clin Oncol. 2014 Dec;140(12):2077-86. doi: 10.1007/s00432-014-1728-x. Epub 2014 Jun 11. PMID: 24916170.
    46. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1301-8. doi: 10.1016/j.cgh.2008.09.014. Epub 2008 Sep 27. PMID: 18948228.
    47. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, Asbun HJ, Bassi C, Büchler M, Charnley RM, Conlon K, Cruz LF, Dervenis C, Fingerhutt A, Friess H, Gouma DJ, Hartwig W, Lillemoe KD, Montorsi M, Neoptolemos JP, Shrikhande SV, Takaori K, Traverso W, Vashist YK, Vollmer C, Yeo CJ, Izbicki JR; International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014 Jun;155(6):977-88. doi: 10.1016/j.surg.2014.02.001. Epub 2014 Feb 7. PMID: 24856119.
    48. Brennan DD, Zamboni GA, Raptopoulos VD, Kruskal JB. Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics. 2007 Nov-Dec;27(6):1653-66. doi: 10.1148/rg.276075034. PMID: 18025509.
    49. Kim HJ, Byun JH, Park SH, Shin YM, Kim PN, Ha HK, Lee MG. Focal fatty replacement of the pancreas: usefulness of chemical shift MRI. AJR Am J Roentgenol. 2007 Feb;188(2):429-32. doi: 10.2214/AJR.05.1095. PMID: 17242252.
    50. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016 Jul 2;388(10039):73-85. doi: 10.1016/S0140-6736(16)00141-0. Epub 2016 Jan 30. PMID: 26830752.
    51. Lee TY, Kim MH, Park DH, Seo DW, Lee SK, Kim JS, Lee KT. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol. 2009 Aug;193(2):343-8. doi: 10.2214/AJR.08.2297. PMID: 19620430.
    52. Chari ST, Takahashi N, Levy MJ, Smyrk TC, Clain JE, Pearson RK, Petersen BT, Topazian MA, Vege SS. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1097-103. doi: 10.1016/j.cgh.2009.04.020. Epub 2009 May 4. PMID: 19410017.
    53. Ghazale A, Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Clain JE, Pearson RK, Pelaez-Luna M, Petersen BT, Vege SS, Farnell MB. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol. 2007 Aug;102(8):1646-53. doi: 10.1111/j.1572-0241.2007.01264.x. Epub 2007 Jun 6. PMID: 17555461.
    54. Kamisawa T, Imai M, Yui Chen P, Tu Y, Egawa N, Tsuruta K, Okamoto A, Suzuki M, Kamata N. Strategy for differentiating autoimmune pancreatitis from pancreatic cancer. Pancreas. 2008 Oct;37(3):e62-7. doi: 10.1097/MPA.0b013e318175e3a0. PMID: 18815540.
    55. Treadwell JR, Zafar HM, Mitchell MD, Tipton K, Teitelbaum U, Jue J. Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma: A Meta-Analysis. Pancreas. 2016 Jul;45(6):789-95. doi: 10.1097/MPA.0000000000000524. PMID: 26745859.
    56. Jeong M, Jeong H. Imaging diagnosis of pancreatic cancer: CT and MRI. In: Kim S, Yamaue H, editors. Pancreatic cancer - With special focus on topical issues and surgical techniques. Springer. 2017; 95-114.
    57. Park HS, Lee JM, Choi HK, Hong SH, Han JK, Choi BI. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging. 2009 Sep;30(3):586-95. doi: 10.1002/jmri.21889. PMID: 19711405.
    58. Kato K, Nihashi T, Ikeda M, Abe S, Iwano S, Itoh S, Shimamoto K, Naganawa S. Limited efficacy of (18)F-FDG PET/CT for differentiation between metastasis-free pancreatic cancer and mass-forming pancreatitis. Clin Nucl Med. 2013 Jun;38(6):417-21. doi: 10.1097/RLU.0b013e3182817d9d. PMID: 23486318.
    59. Okano K, Kakinoki K, Akamoto S, Hagiike M, Usuki H, Yamamoto Y, Nishiyama Y, Suzuki Y. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol. 2011 Jan 14;17(2):231-5. doi: 10.3748/wjg.v17.i2.231. PMID: 21245997; PMCID: PMC3020378.
    60. Kittaka H, Takahashi H, Ohigashi H, Gotoh K, Yamada T, Tomita Y, Hasegawa Y, Yano M, Ishikawa O. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg. 2013 Jan;37(1):169-78. doi: 10.1007/s00268-012-1775-x. PMID: 22955953.
    61. Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zalupski MM, Shields AF. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol. 2010 Jun;33(3):257-61. doi: 10.1097/COC.0b013e3181a76a0b. PMID: 19806035; PMCID: PMC3848057.
    62. Ogawa T, Kawamoto H, Harada R, Kurihara N, Kato H, Hirao K, et al. EUS-FNA is more advantageous than ERCP in tissue sampling for pathological diagnosis of pancreatic cancer. Gastrointest Endosc 2009; 69:S258.
    63. Itoi T, Sofuni A. Endoscopic diagnosis. In: Kim S, Yamaue H, editors. Pancreatic cancer - With special focus on topical issues and surgical techniques. Springer; 2017. 115-22.
    64. Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet. 2000 Jul 15;356(9225):190-3. doi: 10.1016/S0140-6736(00)02479-X. PMID: 10963196.
    65. Satoh T, Kikuyama M, Kawaguchi S, Kanemoto H, Muro H, Hanada K. Acute pancreatitis-onset carcinoma in situ of the pancreas with focal fat replacement diagnosed using serial pancreatic-juice aspiration cytologic examination (SPACE). Clin J Gastroenterol. 2017 Dec;10(6):541-545. doi: 10.1007/s12328-017-0776-6. Epub 2017 Oct 6. PMID: 28986726.
    66. Hanada K, Okazaki A, Hirano N, Izumi Y, Teraoka Y, Ikemoto J, Kanemitsu K, Hino F, Fukuda T, Yonehara S. Diagnostic strategies for early pancreatic cancer. J Gastroenterol. 2015 Feb;50(2):147-54. doi: 10.1007/s00535-014-1026-z. Epub 2014 Dec 14. PMID: 25501287.
    67. Mikata R, Ishihara T, Tada M, Tawada K, Saito M, Kurosawa J, Sugiyama H, Sakai Y, Tsuyuguchi T, Miyazaki M, Yokosuka O. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso-pancreatic drainage tube in patients with pancreatic cancer. J Gastroenterol. 2013 Jul;48(7):866-73. doi: 10.1007/s00535-012-0684-y. Epub 2012 Oct 10. PMID: 23053424.
    68. DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, Ciaccia D, Lane KA, Maglinte D, Kopecky K, LeBlanc J, McHenry L, Madura J, Aisen A, Cramer H, Cummings O, Sherman S. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med. 2004 Nov 16;141(10):753-63. doi: 10.7326/0003-4819-141-10-200411160-00006. PMID: 15545675.
    69. Müller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging. Radiology. 1994 Mar;190(3):745-51. doi: 10.1148/radiology.190.3.8115622. PMID: 8115622.
    70. Faigel DO, Kochman ML. The role of endoscopic ultrasound in the preoperative staging of pancreatic malignancies. Gastrointest Endosc. 1996 Jun;43(6):626-8. doi: 10.1016/s0016-5107(96)70206-7. PMID: 8781948.
    71. Aslanian H, Salem R, Lee J, Andersen D, Robert M, Topazian M. EUS diagnosis of vascular invasion in pancreatic cancer: surgical and histologic correlates. Am J Gastroenterol. 2005 Jun;100(6):1381-5. doi: 10.1111/j.1572-0241.2005.41675.x. PMID: 15929774.
    72. Itokawa F, Itoi T, Sofuni A, Kurihara T, Tsuchiya T, Ishii K, Tsuji S, Ikeuchi N, Umeda J, Tanaka R, Yokoyama N, Moriyasu F, Kasuya K, Nagao T, Kamisawa T, Tsuchida A. EUS elastography combined with the strain ratio of tissue elasticity for diagnosis of solid pancreatic masses. J Gastroenterol. 2011 Jun;46(6):843-53. doi: 10.1007/s00535-011-0399-5. Epub 2011 Apr 20. PMID: 21505859.
    73. Săftoiu A, Vilmann P, Gorunescu F, Janssen J, Hocke M, Larsen M, Iglesias-Garcia J, Arcidiacono P, Will U, Giovannini M, Dietrich CF, Havre R, Gheorghe C, McKay C, Gheonea DI, Ciurea T; European EUS Elastography Multicentric Study Group. Efficacy of an artificial neural network-based approach to endoscopic ultrasound elastography in diagnosis of focal pancreatic masses. Clin Gastroenterol Hepatol. 2012 Jan;10(1):84-90.e1. doi: 10.1016/j.cgh.2011.09.014. Epub 2011 Oct 1. PMID: 21963957.
    74. Ying L, Lin X, Xie ZL, Hu YP, Tang KF, Shi KQ. Clinical utility of endoscopic ultrasound elastography for identification of malignant pancreatic masses: a meta-analysis. J Gastroenterol Hepatol. 2013 Sep;28(9):1434-43. doi: 10.1111/jgh.12292. PMID: 23731128.
    75. Mei M, Ni J, Liu D, Jin P, Sun L. EUS elastography for diagnosis of solid pancreatic masses: a meta-analysis. Gastrointest Endosc. 2013 Apr;77(4):578-89. doi: 10.1016/j.gie.2012.09.035. Epub 2012 Nov 27. PMID: 23199646.
    76. Gong TT, Hu DM, Zhu Q. Contrast-enhanced EUS for differential diagnosis of pancreatic mass lesions: a meta-analysis. Gastrointest Endosc. 2012 Aug;76(2):301-9. doi: 10.1016/j.gie.2012.02.051. Epub 2012 Jun 15. PMID: 22703697.
    77. Puli SR, Bechtold ML, Buxbaum JL, Eloubeidi MA. How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: A meta-analysis and systematic review. Pancreas. 2013 Jan;42(1):20-6. doi: 10.1097/MPA.0b013e3182546e79. PMID: 23254913.
    78. Chen G, Liu S, Zhao Y, Dai M, Zhang T. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a meta-analysis. Pancreatology. 2013 May-Jun;13(3):298-304. doi: 10.1016/j.pan.2013.01.013. Epub 2013 Feb 10. PMID: 23719604.
    79. Hébert-Magee S, Bae S, Varadarajulu S, Ramesh J, Frost AR, Eloubeidi MA, Eltoum IA. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. Cytopathology. 2013 Jun;24(3):159-71. doi: 10.1111/cyt.12071. PMID: 23711182; PMCID: PMC4159090.
    80. Matsuyama M, Ishii H, Kuraoka K, Yukisawa S, Kasuga A, Ozaka M, Suzuki S, Takano K, Sugiyama Y, Itoi T. Ultrasound-guided vs endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer diagnosis. World J Gastroenterol. 2013 Apr 21;19(15):2368-73. doi: 10.3748/wjg.v19.i15.2368. PMID: 23613631; PMCID: PMC3631989.

類似の記事

The Educational Role of Cinema in Physical Sciences
Maria Sagri, Denis Vavougios and Filippos Sofos
DOI10.61927/igmin121
On how Doping with Atoms of Gadolinium and Scandium affects the Surface Structure of Silicon
Egamberdiev BE, Daliev Kh S, Khamidjonov I Kh, Norkulov Sh B and Erugliev UK
DOI10.61927/igmin206
Potentially Toxic Metals in Cucumber Cucumis sativus Collected from Peninsular Malaysia: A Human Health Risk Assessment
Chee Kong Yap, Rosimah Nulit, Aziran Yaacob, Zaieka Shamsudin, Meng Chuan Ong, Wan Mohd Syazwan, Hideo Okamura, Yoshifumi Horie, Chee Seng Leow, Ahmad Dwi Setyawan, Krishnan Kumar, Wan Hee Cheng and Kennedy Aaron Aguol
DOI10.61927/igmin200
Peritoneal Carcinomatosis from Ovarian Cancer: A Case Report
Andrea González De Godos, Enrique Asensio Diaz, Pilar Pinto Fuentes, Baltasar Pérez Saborido and David Pacheco Sánchez
DOI10.61927/igmin181
研究を公開する

私たちは、科学、技術、工学、医学に関する幅広い種類の記事を編集上の偏見なく公開しています。

提出する

見る 原稿のガイドライン 追加 論文処理料

IgMin 科目を探索する
グーグルスカラー
welcome Image

Google Scholarは2004年11月にベータ版が発表され、幅広い学術領域を航海する学術ナビゲーターとして機能します。それは査読付きジャーナル、書籍、会議論文、論文、博士論文、プレプリント、要約、技術報告書、裁判所の意見、特許をカバーしています。 IgMin の記事を検索